Status:
COMPLETED
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Advanced Hormone Dependent Prostate Cancer
Eligibility:
MALE
18-100 years
Brief Summary
Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina
Eligibility Criteria
Inclusion
- Advanced Prostate Cancer patients to be treated with Firmagon in the context of usual clinical practice
- Written informed consent
Exclusion
- Contraindications to Firmagon
- Patients already on Firmagon therapy
Key Trial Info
Start Date :
March 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 3 2018
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT01861236
Start Date
March 1 2013
End Date
September 3 2018
Last Update
October 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Trauma y Emergencia Dr Federico Abete
Ingeniero Pablo Nogués, Buenos Aires, Argentina